Eli Lilly's preliminary 2024 revenue fell short due to lower sales of weight loss and diabetes shots, with expected $45 billion revenue below analysts' $45.5 billion estimate.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Eli Lilly misses 2024 revenue numbers, but GLP-1 pill may help
